Ligation of CD11c during vaccination promotes germinal centre induction and robust humoral responses without adjuvant.
In this study, we investigated the mouse dendritic cell (DC) receptor, complement receptor 4 (CR4; CD11c/CD18), as an immunotarget for triggering humoral immunity. Comparison of antibody titres generated against a panel of 13 anti-antigen-presenting cell receptor monoclonal antibodies, with or without conjugated ovalbumin (OVA), revealed uniquely rapid and robust responses following CR4 targeting, with antibody titres approaching 1 : 100 000 7 days after a single dose of antigen. Furthermore, using just 100 ng OVA conjugated to anti-CD11c Fab', we generated anti-OVA titres greater than those produced by a 100-fold higher dose of OVA in complete Freund's adjuvant at day 28. These anti-OVA antibody titres were sustained and could be boosted further with targeted OVA on day 21. Investigations to explain this vaccine potency showed that, in addition to targeting splenic DC, anti-CDl1c antibodies delivered a powerful adjuvant effect and could boost humoral immunity against OVA even when the OVA was targeted to other molecules on DC, such as major histocompatibility complex class II, CD11a and CD11b. However, interestingly, this adjuvant effect was lost if OVA was targeted to other cells such as B cells via CD21 or CD19. The adjuvant effect was mediated through a marked enhancement of both germinal centre and extrafollicular plasma cell formation in responding spleens. These results demonstrate that anti-CD11c monoclonal antibody can both target antigen and act as a powerful adjuvant for rapid and sustained antibody responses. They also point to an interesting role for CR4 on DC in triggering B cells during humoral immunity.
White
Ann L
AL
Tenovus Research Laboratory, Cancer Sciences Division, Southampton University School of Medicine, General Hospital, Southampton, UK.
Tutt
Alison L
AL
James
Sonya
S
Wilkinson
Kevin A
KA
Castro
Fernanda V V
FV
Dixon
Sandra V
SV
Hitchcock
Jessica
J
Khan
Mahmood
M
Al-Shamkhani
Aymen
A
Cunningham
Adam F
AF
Glennie
Martin J
MJ
D000276:Adjuvants, Immunologic; D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000276:immunology; D000917:Antibody Formation / Q000276:immunology*; D017951:Antigen Presentation; D000938:Antigen-Presenting Cells / Q000276:immunology; D039521:CD11c Antigen / Q000276:immunology* / Q000378:metabolism*; D003713:Dendritic Cells / Q000276:immunology; D018858:Germinal Center / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D010047:Ovalbumin / Q000008:administration & dosage / Q000276:immunology; D014611:Vaccination
D000276:Adjuvants, Immunologic; D000911:Antibodies, Monoclonal; D039521:CD11c Antigen; D010047:Ovalbumin
Annu Rev Immunol. 2003;21:685-711
12615891
J Immunol. 1998 Sep 15;161(6):3176-85
9743386
Semin Immunol. 1997 Oct;9(5):293-301
9327524
J Immunol Methods. 1999 Feb 1;223(1):77-92
10037236
Immunity. 2009 Feb 20;30(2):264-76
19185517
Immunol Cell Biol. 2008 Jan;86(1):31-9
18026175
Science. 2006 Jun 16;312(5780):1672-6
16778060
Eur J Immunol. 2008 Aug;38(8):2263-73
18651710
J Immunol. 2005 Dec 1;175(11):7125-34
16301615
J Immunol. 1999 Oct 15;163(8):4125-32
10510347
Proc Natl Acad Sci U S A. 2009 Mar 24;106(12):4782-7
19255434
J Immunol. 2002 Sep 15;169(6):2900-6
12218103
J Exp Med. 1997 Mar 3;185(5):941-51
9120400
Nature. 1987 May 7-13;327(6117):59-61
3472080
Mol Immunol. 1991 Mar;28(3):261-7
1708106
Nature. 2007 Nov 1;450(7166):110-4
17934446
Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):847-52
10639168
J Immunol. 1993 Oct 1;151(7):3557-68
8376792
J Immunol. 1998 Aug 1;161(3):1313-9
9686593
Nat Med. 2006 Feb;12(2):207-13
16444266
Scand J Immunol. 1998 Dec;48(6):563-70
9874489
Nature. 1998 Mar 19;392(6673):245-52
9521319
Biochem J. 1985 Oct 1;231(1):233-6
4062888
Science. 2007 Jan 5;315(5808):107-11
17204652
Immunity. 2007 Jul;27(1):160-71
17658276
Immunity. 2009 Mar 20;30(3):324-35
19303387
J Immunol. 2007 May 15;178(10):6200-7
17475847
Curr Opin Immunol. 2007 Jun;19(3):275-80
17433651
Eur J Immunol. 2006 Nov;36(11):2912-9
17051619
Hybrid Hybridomics. 2003 Feb;22(1):23-31
12713687
Immunity. 2007 Apr;26(4):491-502
17379546
Nat Immunol. 2007 Sep;8(9):992-1000
17660822
Immunity. 2005 Nov;23(5):503-14
16286018
Mol Immunol. 2005 May;42(8):979-85
15829289
Nat Rev Immunol. 2002 Mar;2(3):151-61
11913066
Immunol Rev. 2007 Aug;218:197-213
17624954
J Immunol. 2008 Jul 15;181(2):1375-85
18606692
Eur J Immunol. 1999 Nov;29(11):3712-21
10556827
Immunol Today. 2000 Sep;21(9):436-41
10953095
J Immunol. 1996 Aug 15;157(4):1406-14
8759720
J Biol Chem. 2000 Aug 4;275(31):23409-12
10801898
Int Immunopharmacol. 2001 Feb;1(2):265-75
11360928
J Immunol. 2009 Feb 15;182(4):2113-23
19201864
J Exp Med. 2008 Nov 24;205(12):2873-86
18981236
Eur J Immunol. 2005 Oct;35(10):2815-25
16143986
J Immunol. 1987 Feb 1;138(3):981-8
2433338
Blood. 2008 Oct 15;112(8):3264-73
18669894
Vaccine. 2005 Nov 16;23(46-47):5450-6
16006019
Mol Pharm. 2007 Jan-Feb;4(1):58-72
17228857
J Immunol. 2004 Aug 15;173(4):2297-306
15294942
J Exp Med. 1999 Sep 20;190(6):851-60
10499923
Proc Natl Acad Sci U S A. 1982 Jan;79(1):161-5
6948298
J Exp Med. 1990 May 1;171(5):1753-71
2185332
Eur J Immunol. 2004 Nov;34(11):2986-95
15384042
Semin Immunol. 1992 Aug;4(4):275-83
1391800
Nature. 2005 Nov 17;438(7066):364-8
16292312
Science. 2006 Dec 22;314(5807):1936-8
17185603
J Exp Med. 2000 Sep 18;192(6):813-21
10993912